The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

John Mendelsohn, MD, an internationally acclaimed leader in the medical field died January 7 at his home in Houston, Texas at the age of 82.

Waun Ki Hong, MD, a pioneering medical oncologist recognized for his practice-changing research in head and neck cancer, died at his home in California on January 2.

Researchers from the University of Texas MD Anderson Cancer Center in Houston, TX compared how various prostate cancer treatments compare on cost and adverse effects.

Results of a new study show that adding ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival (PFS) when used as a first-line treatment for

Jan Lewin, PhD, section chief of Speech Pathology at the University of Texas MD Anderson Cancer Center, discusses head and neck lymphedema.

Ovarian cancer expert, David M. Gershenson, MD, from University of Texas MD Anderson Cancer Center discusses three treatments for some of the rare types of ovarian cancers and the challenges to treating these diseases.

Partow Kebriaei, MD, from MD Anderson Cancer Center, discusses how nurses can monitor patients for cytokine release syndrome.

Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.

Ignacio I. Wistuba, MD, chair of the department of Translational Molecular Pathologies at MD Anderson Cancer Center, discusses the role nurses play in the field of molecular testing.

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at University of Texas MD Anderson Cancer Center, discusses genetic risk for breast cancer, the strongest factor in determining if an individual will develop the disease.

Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses low sexual desire in breast cancer survivors.